![]() |
Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC
Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
More... |
| All times are GMT -7. The time now is 09:42 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021